3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
4
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
549
Lung Neoplasms
312
Small Cell Lung Carcinoma
87
Colorectal Neoplasms
71
Melanoma
68
Breast Neoplasms
60
Neoplasms
55
Ovarian Neoplasms
47
Neoplasm Metastasis
45
Carcinoma, Renal Cell
45
Squamous Cell Carcinoma of Head and Neck
43
Pancreatic Neoplasms
39
Stomach Neoplasms
37
Triple Negative Breast Neoplasms
31
Head and Neck Neoplasms
30
Esophageal Neoplasms
28
Endometrial Neoplasms
25
Prostatic Neoplasms
24
Uterine Cervical Neoplasms
23
Urinary Bladder Neoplasms
23
Brain Neoplasms
22
Colonic Neoplasms
21
Mesothelioma
20
Mesothelioma, Malignant
18
Carcinoma, Hepatocellular
18
Sarcoma
16
Carcinoma, Transitional Cell
15
Adenocarcinoma of Lung
15
Lung Diseases
14
NSCLC
13
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Non Small Cell Lung Cancer NSCLC
×
Thoracic
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA